{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"100"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"1"}],"units":"Participants"}],"groups":[{"description":"Participants with locally advanced or metastatic ALK-positive tumors were to receive alectinib twice daily (BID) until disease progression, unacceptable toxicity, death, or withdrawal from the study for any reason.","id":"OG000","title":"ALK-positive Solid Tumors"}],"paramType":"NUMBER","reportingStatus":"POSTED","timeFrame":"Approximately 1 year","title":"Percentage of Participants With Adverse Events (AEs)","type":"SECONDARY","unitOfMeasure":"Percentage"}